Goldman Sachs Downgrades Alere (ALR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Jefferies Downgrades Alere (ALR) to Hold Following Takeover
February 2, 2016 7:58 AM ESTJefferies downgraded Alere (NYSE: ALR) from Buy to Hold with a price target of $56.00 (from $54.00) after the company agreed to be acquired by Abbott Laboratories.
For an analyst ratings summary and ratings history on Alere... More
Canaccord Genuity Downgrades Alere (ALR) to Hold
February 2, 2016 7:55 AM ESTCanaccord Genuity downgraded Alere (NYSE: ALR) from Buy to Hold.
For an analyst ratings summary and ratings history on Alere click here. For more ratings news on Alere click here.
Shares of Alere closed at $54.11 yesterday.
... MoreAbbott (ABT) to Acquire Alere (ALR) for $56/Share
February 1, 2016 8:02 AM ESTAbbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership. Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion. Once the transaction is completed, Abbott will become the leading diagnostics provider of point of care testing. Abbott's total diagnostics sales will exceed $7 billion after the close.
Abbott will be able to provide new, flexible, cost-effective, high-quality products to help health systems meet... More
